We are live on ! Find out more
NTLA icon

Intellia Therapeutics

141 hedge funds and large institutions have $430M invested in Intellia Therapeutics in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 40 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $1.43M

5.23% more ownership

Funds ownership: 67.37%72.6% (+5.2%)

5% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 40

10% less funds holding

Funds holding: 157141 (-16)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

42% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 36

48% less capital invested

Capital invested by funds: $833M → $430M (-$403M)

Holders
141
Holders Change
-16
Holders Change %
-10.19%
% of All Funds
3.14%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
21
Increased
42
Reduced
40
Closed
36
Calls
$2.21M
Puts
$1.43M
Net Calls
+$777K
Net Calls Change
+$4.25M
Name Holding Trade Value Shares
Change
Change in
Stake
WAM
101
Wealthspire Advisors (Maryland)
Maryland
$33K
BFEC
102
Benjamin F. Edwards & Company
Missouri
$31K
MOS
103
MGO One Seven
Ohio
$28K +$39K +2,100 New
PFO
104
Pathstone Family Office
New Jersey
$25K
SWM
105
SeaCrest Wealth Management
New York
$19K -$3.72K -200 -13%
OIA
106
Optimum Investment Advisors
Illinois
$18K -$9.29K -500 -28%
IA
107
IFP Advisors
Florida
$16K +$4.65K +250 +26%
SSB
108
Sandy Spring Bank
Maryland
$14K
TIM
109
Tortoise Investment Management
New York
$14K
PRC
110
Pearl River Capital
Michigan
$12K +$17K +915 New
GWM
111
Geneos Wealth Management
Colorado
$11K +$17K +917 New
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
$10K -$69.9K -3,759 -84%
AWM
113
Aevitas Wealth Management
Massachusetts
$10K
MFW
114
Mosaic Family Wealth
Missouri
$7K
APA
115
American Portfolios Advisors
New York
$6.26K -$2.42K -130 -22%
Bank of Montreal
116
Bank of Montreal
Ontario, Canada
$6K -$10.4K -561 -55%
WT
117
Whittier Trust
California
$5K
RCAG
118
Rehmann Capital Advisory Group
Michigan
$4.5K -$262K -14,079 -98%
KBC Group
119
KBC Group
Belgium
$4K -$4.93K -265 -50%
SIA
120
SeaBridge Investment Advisors
New Jersey
$4K
TCM
121
Tradewinds Capital Management
Washington
$4K +$558 +30 +13%
Macquarie Group
122
Macquarie Group
Australia
$4K +$3.72K +200 +200%
QT
123
Quantamental Technologies
New York
$4K +$4.83K +260 New
RE
124
RBC Europe
United Kingdom
$3.89K
CB
125
CNB Bank
Pennsylvania
$3K

NTLA Hedge Fund Activity: Q4 2018 in Review

141 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2018, worth a combined $430M — down 48% from $833M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of NTLA and 21 opened new positions — a net loss of 15 holders — while 40 trimmed existing stakes and 42 added.

The largest buyer was Ontario Teachers' Pension Plan Board, opening a new position worth an estimated $30.9M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $15.7M sold.

  • 141 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2018, down from 157 in Q3 2018.
  • Funds reported $430M of Intellia Therapeutics stock for Q4 2018, down 48% quarter-over-quarter.
  • 21 funds opened new Intellia Therapeutics positions in Q4 2018 and 36 closed out, a net change of -15 holders.
  • The largest Intellia Therapeutics buyer in Q4 2018 was Ontario Teachers' Pension Plan Board, an estimated $30.9M added.
  • The largest Intellia Therapeutics seller in Q4 2018 was Farallon Capital Management, an estimated $15.7M sold.

Based on aggregated 13F filings for Q4 2018.